That's the market, not the company. We should get an announcement regards the ATI trials to date when they complete recruitment in 1Q 2020. I would not want to sell ahead of a likely announcement from J&J, who commissioned the trial, on a joint partnership and possible funding. If you saw the spikes on CelGro success I think you can imagine the spike if an ATI partnership is announced with J&J (which I strongly believe will happen).
The company was tardy in getting recruitment complete, but what can they do if people don't want to sign up to the trial - Australian's just don't seem inclined to embrace these more forward approaches to chronic ailments at their loss. Similarly the market is somewhat out of the company's control.
This is a buying opportunity for those with big pockets, an arduous wait for the rest of us.
OCC Price at posting:
47.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)